At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 81 enrolled
Drug / intervention
CardioFocus EAS-ACdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation
In Brief
A Phase 3 clinical trial evaluating CardioFocus EAS-AC for Paroxysmal Atrial Fibrillation. Completed, enrolled 81 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of the endoscopic ablation system - adaptive contact (EAS-AC) in treated paroxysmal atrial fibrillation (PAF) with pulmonary vein isolation (PVI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Atrial Fibrillation
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionMar 2012
Study CompletionMay 2012
TodayJul 2026
First PostedAug 13, 2009
Enrollment StartAug 1, 2009
Primary CompletionMar 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.9 years ago
Interventions
CardioFocus EAS-ACdevice
PVI for PAF